January 13th 2020
Robert L. Coleman, MD, discusses the next steps of treatment for patients with high-grade serous ovarian cancer.
January 20th 2019
Robert L. Coleman, MD, FACOG, FACS, professor, Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, discusses advances made in the treatment of ovarian cancer.
September 11th 2015
Robert L. Coleman, MD, The University of Texas MD Anderson Cancer Center, discusses the next steps following results of the ARIEL2 trial, which aimed to identify patients with ovarian cancer most likely to respond to rucaparib using tumor genetic analysis.